Peter van de Sande, MSc, MBA, MBL
Chief Executive Officer
Prior to joining Synaffix in 2011, Peter held various executive positions at CPS Color (now Chromaflo/Corob), including Managing Director Australia, Director Marketing & Sales APAC, Global Product Manager and Technical & Business Development Director. He received his MSc degree in Chemical Engineering from Eindhoven University of Technology (the Netherlands), an Executive MBA degree from Kellogg School of Management and a Master of Business Law (MBL) degree from Sydney University (Australia).
Floris van Delft, PhD
Founder & Chief Scientific Officer
Floris held a position as Associate Professor at the Radboud University Nijmegen, with special focus on click chemistry and protein conjugation technologies, before shifting his professional activities full-time from academic research to Synaffix in 2012. Earlier appointments involved a postdoctoral research position at the Scripps Research Institute (San Diego, USA) and an assistant professorship at the University of Amsterdam. Floris received his MSc and PhD (cum laude) from Leiden University (the Netherlands) in carbohydrate chemistry and stereoselective synthesis. He has authored >130 peer-reviewed publications, 14 patents and serves as the Professor of Bioconjugate Chemistry at Wageningen University in the Netherlands.
Sander van Berkel, PhD
Founder & Director, R&D Operations
Prior to Synaffix, Sander performed postdoctoral research on novel conjugation methodologies for non-invasive cancer imaging at University of Oxford. Preceding Oxford, he worked at the Leibniz-Institute of Plant Biochemistry in Halle, Germany, as postdoctoral researcher focusing on the synthesis of antitumor agent epothilone B and its derivatives. He holds a PhD and a MSc in Organic Chemistry from the Radboud University Nijmegen, the Netherlands. He is an inventor on several patents and has been author of 31 peer-reviewed publications and reviews.
Director, Business Development
Prior to joining Synaffix in 2014, Anthony served as the Associate Director of Business Development at Allozyne, a Seattle-based biotech, where he was focused on partnering efforts around pipeline programs and antibody-drug conjugate technology leading up to an acquisition by MedImmune. Previously, he studied in the laboratory of Dr. Irv Weissman at the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Anthony is a published co-author in Nature and PNAS and holds a BSc in Biotechnology from Seattle Pacific University.